| Autor: |
Peng Li, Amani Makkouk, Jennifer Gordetsky, Eddy Yang, Lewis Thomas, Lakshminarayanan Nandagopal, Hesham Yasin, Rohan Garje, Shannon K Boi, Rachael M Orlandella, Justin Tyler Gibson, William James Turbitt, Gal Wald, Claire Buchta Rosean, Katlyn E Norris, Megan Bing, Laura Bertrand, Brett P Gross, Dmytro Starenki, Kristine I Farag, Robert E Sorge, James A Brown, David M Lubaroff, Rebecca C Arend, Kenneth Nepple, Tatiana T Marquez-Lago, Lyse A Norian |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2051-1426 |
| DOI: |
10.1136/jitc-2020-000725 |
| Popis: |
Background Obesity is a major risk factor for renal cancer, yet our understanding of its effects on antitumor immunity and immunotherapy outcomes remains incomplete. Deciphering these associations is critical, given the growing clinical use of immune checkpoint inhibitors for metastatic disease and mounting evidence for an obesity paradox in the context of cancer immunotherapies, wherein obese patients with cancer have improved outcomes.Methods We investigated associations between host obesity and anti-programmed cell death (PD-1)-based outcomes in both renal cell carcinoma (RCC) subjects and orthotopic murine renal tumors. Overall survival (OS) and progression-free survival (PFS) were determined for advanced RCC subjects receiving standard of care anti-PD-1 who had ≥6 months of follow-up from treatment initiation (n=73). Renal tumor tissues were collected from treatment-naive subjects categorized as obese (body mass index, ‘BMI’ ≥30 kg/m2) or non-obese (BMI |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
